Antibody levels were quantified at 1:100 serum dilution as median fluorescence intensity (MFI) and dichotomized as positive or negative based on previously defined cutpoints[3, 15]. Clinical HPV testing As part of clinical management, p16 overexpression and HPV DNA ISH were available for a subset of patients. HPV-OPC and HPV16-OPC from HPV-negative OPC, b) HPV16E6 antibody decay post-treatment using linear models accommodating correlations in variance estimates and c) pre- and post-treatment HPV16E6 levels and risk of recurrence using Cox proportional hazards models. RESULTS Of 87 HPV-OPCs, 78 were HPV16E6 seropositive; sensitivity: 89.7% (95%CI: 81.3%C95.2%) and 24 of 25 ACVRLK4 HPV-negative OPCs were HPV16E6 seronegative; specificity: 96.0% (95%CI: 79.6%C99.9%). 42 of 45 HPV16-OPCs were HPV16E6 seropositive; sensitivity: 93.3% (95%CI: 81.7%C98.6%) and 18 of 19 HPV16-negative OPCs were HPV16 E6 seronegative; specificity: 94.7% (95%CI: 74.0%C99.9%). Post-treatment HPV16E6 antibody levels did Pefloxacin mesylate not decrease significantly from baseline (hybridization (ISH) and combined HPV DNA and RNA analysis, respectively. MATERIALS AND METHODS Study Populace Incident, previously Pefloxacin mesylate untreated, cases of OPC were recognized using an IRB-approved protocol (UPCI 99-069) that collects baseline serum at the University or college of Pittsburgh Malignancy Institute; all patients provided written informed consent. Since the establishment of the biobank in 2000, a total of 1 1,462 patients with OPC (ICD10 codes: C01.0, C02.4, C05.1, C05.2, C05.8, C09.0, C09.1, C09.8, C09.9, C10.0, C10.2, C10.3, C10.8, C10.9, C14.0) were treated; 939 (64%) were enrolled as part of the tissue banking study. Of the 860 incident Pefloxacin mesylate cases, 720 (84%) experienced serum samples collected prior to treatment, of which, 112 (17%) experienced concurrent p16 IHC and HPV ISH test results available as part of clinical management. HPV antibody screening was conducted on pre-treatment serum samples from all incident cases of HPV-OPC (p16 and HPV ISH dual positives, N=87) and HPV-negative OPC (p16 and HPV ISH dual negatives, N=25). Screening of serial samples was conducted for the subset of patients (N=35 of 87) who experienced 1C2 post-treatment samples available. Additionally, we chose to test serial samples from all HPV indeterminate OPCs (discordant or missing p16 IHC and HPV ISH results) for which post-treatment samples were available under the assumption that the majority would be HPV16E6 seropositive pre-treatment; thus increasing our power to assess changes in HPV16E6 levels post-treatment and risk of recurrence. However, serum samples from 22 HPV-indeterminate patients were erroneously tested under the belief they had post-treatment serial samples (Supplemental Physique 1). Eighty-six tumors were recovered for HPV16-type specific DNA and RNA screening. Those with concordant HPV16 DNA/RNA positive results were defined as HPV16-driven (HPV16-OPC); those with concordant negative results were defined as HPV16-negative and those with discordant results were considered indeterminate. Laboratory Methods Serologic Screening Multiplex serologic screening was performed at the German Malignancy Research Center (Heidelberg, Germany) by staff blinded to the HPV status of the patients[11C14]. Antigens were affinity-purified, bacterially expressed fusion proteins with N-terminal Glutathione S-transferase. Samples were analyzed for antibodies against HPV16 L1, E1, E2, E4, E6, and E7 and the E6 protein from HPV6, HPV11, HPV18, HPV31, HPV33, HPV45 and HPV58. Antibody levels were quantified at 1:100 serum dilution as median fluorescence intensity (MFI) and dichotomized as positive or unfavorable based on previously defined cutpoints[3, 15]. Clinical HPV screening As part of clinical management, p16 overexpression and HPV DNA ISH were available for a subset of patients. p16 IHC was conducted on deparaffinized tissue sections using the monoclonal antibody clone G175C405 against p16INK4 (dilution 1:200; BD Pharmingen, San Diego, CA); immunoreactivity in 70% of cells was considered positive[16, 17]. ISH was performed with a probe set specific for 10 HPV types (Dako Cytomation, Carpinteria, CA). HPV type-specific screening Formalin-fixed paraffin-embedded (FFPE) tissue samples were consecutively sectioned for DNA and RNA analysis; the first and the last sections were stained by hematoxylin and eosin to verify the presence of tumor[18]. DNA and RNA were extracted from FFPE sections as previously explained[18]; water samples were included to monitor possible cross-contamination. HPV DNA analysis was carried out using Multiplex Papillomavirus Genotyping[19, 20] homogenously amplifying and specifically detecting 51 HPV types, three subtypes and cellular beta-globin as internal DNA quality control. Samples that were positive for HPV and/or positive for cellular beta-globin DNA were considered DNA valid. HPV RNA analysis, i.e. Pefloxacin mesylate detection of viral transcripts, was performed by HPV type-specific RT-PCR and hybridization[18] assays developed for 20 unique HPV types. These assays amplify HPV E6*I and ubiquitin C (ubC) cDNA as a cellular mRNA quality control. Specimens that.
